Poseida Therapeutics Inc Net Income per Employee (PSTX), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Poseida Therapeutics Inc   (NASDAQ: PSTX)
 

Poseida Therapeutics Inc Net Income per Employee

PSTX's Quarterly Results, Trends, Rankings, Statistics
Poseida Therapeutics Inc recorded a cumulative net loss of $-61 million during 12 month ending in the third quarter 2024.
The Healthcare sector has seen employees of 29 other companies achieving higher income per employee. While Poseida Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 2766 to 3111.


What is Income per Employee Ratio?






PSTX Net Income per Employee (Sep 30 2024)
III. Quarter
(Jun 30 2024)
II. Quarter
(Mar 31 2024)
I. Quarter
(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -184,118 -341,733 -329,870 -374,030 -400,033
PSTX's Total Ranking # 3111 # 2766 # 0 # 0 # 2959
Seq. Net Income Change - - - - -


PSTX Net Income per Employee Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 30
Healthcare Sector # 341
Overall Market # 3111

Net Income per Employee Statistics
High Average Low
$ -88,530 $ -294,701 $ -487,445
(Sep 30 2022)   (Sep 30 2021)







Companies with similar Income per Employee for 12 month ending Sep 30 2024, within Healthcare Sector Income per Employee Income 12 month ending Sep 30 2024Number of Employees Sep 30 2024


Date modified: 2026-08-29T17:42:00+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.